3 completed, 1 terminated. 2 Phase 4, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Formycon AG: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Similar Efficacy, Safety, and Immunogenicity of FYB206 in Comparison to Keytruda as add-on to Chemotherapy in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) FYB206, Keytruda - Non Small Cell Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | Terminated | Formycon AG | 25 | 2024-10-03 | 2025-06-26 |
| Ocular Safety and Usability Study for FYB203 PFS FYB203 2 mg (0.05 mL of 40 mg/mL) - Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema | Phase 4 | Completed | Formycon AG | 30 | 2024-09-20 | 2024-11-27 |
| Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients FYB206, Keytruda - Melanoma, Stage II, Melanoma Stage III | Phase 1 | Completed | Formycon AG | 96 | 2024-07-01 | 2026-10-20 |
| Ocular Safety and Usability Study for FYB201 PFS FYB201 0.5 mg (0.05 mL of 10 mg/mL) - Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema | Phase 4 | Completed | Formycon AG | 31 | 2024-06-11 | 2024-11-27 |
Macular Degeneration (2) · Carcinoma, Non-Small-Cell Lung (1) · Diabetic Retinopathy (1) · Lung Neoplasms (1) · Melanoma (1)
pembrolizumab (2)
Georgia (2) · United States (2) · Bosnia and Herzegovina (1) · Bulgaria (1) · Estonia (1) · Lithuania (1) · Malaysia (1) · Moldova (1) · North Macedonia (1) · Poland (1) · Romania (1) · Serbia (1) · Turkey (Türkiye) (1) · Ukraine (1)
2023 (2)